Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 1/2 1Phase 1 1

Status

Completed 3

Sponsor Class

NIH 6OTHER 4INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 2Thoracic 1

Conditions

Glioblastoma 2Metatropic dwarfism 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

Carboplatin 272Paclitaxel 267Gemcitabine 244Bevacizumab 225Cisplatin 216pembrolizumab 213Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 99Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 80Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Ipilimumab 64Bortezomib 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × Cilengitide × Clear all
NCT00093964 2019-04-16

Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)

EMD Serono

Phase 2 Completed
81 enrolled 21 charts
CNS

Brain Neoplasms, Glioblastoma

NCT00813943 2017-01-30

CORE

EMD Serono

Phase 2 Completed
265 enrolled 20 charts
CNS

Glioblastoma

NCT00842712 2017-01-13

CERTO

Merck KGaA, Darmstadt, Germany

Phase 2 Completed
232 enrolled 17 charts
Thoracic

Metatropic dwarfism, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡